I
Innaterepair
This preclinical-stage biotech develops novel cancer therapeutics by targeting the Hes3 Signaling Axis, a mechanism exploited by cancer stem cells. The company utilizes siRNA technology to selectively target this axis, offering a new approach against aggressive tumors like glioblastoma. Their validated science focuses on inhibiting cancer cell regeneration where current therapies often fail.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This preclinical-stage biotech develops novel cancer therapeutics by targeting the Hes3 Signaling Axis, a mechanism exploited by cancer stem cells. The company utilizes siRNA technology to selectively target this axis, offering a new approach against aggressive tumors like glioblastoma. Their validated science focuses on inhibiting cancer cell regeneration where current therapies often fail.